NEW YORK (360Dx) – Bio-Techne said after the close of the market on Wednesday that it has completed its acquisition of Exosome Diagnostics for up to $575 million.
The deal was originally announced in late June. Bio-Techne paid $250 million in cash up front and could pay up to an additional $325 million contingent on the achievement of certain future milestones. The company had previously stated it would finance the deal through a combination of cash on hand and a revolving line of credit facility.Â
Bio-Techne is scheduled to release its financial results on Aug. 7 before the market opens.
Exosome, which is based in Waltham, Massachusetts, markets a urine-based test called ExoDx Prostate (IntelliScore) to help clinicians determine whether a patient with an ambiguous PSA test needs a prostate biopsy.